Skip to main content

Legal Update

FTC Challenges Consummated Drug Acquisition; Two Commissioners Suggest Sale to Firm Unconstrained by Reputation to Keep Prices Low Could Violate Section 7

23 December 2008
Mayer Brown Legal Update
23 December 2008 - Signs of aggressive new merger enforcement positions are evident in the Federal Trade Commission's challenge of the acquisition of a drug to treat a heart condition in premature babies. In Federal Trade Commission v. Ovation Pharmaceuticals, Inc., No. 08-cv-06379-JNE-JJG (D. Minn. Dec. 16, 2008), the FTC alleges that the acquisition, which has already been consummated, made Ovation the owner of the only two drugs currently approved to treat this condition.


  • Christopher J. Kelly
    T +1 650 331 2025
  • Richard M. Steuer
    Senior Counsel, Independent Contractor
    T +1 212 506 2530
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.